
Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.
Johnson & Johnson's investigational prostate cancer drug JNJ-6143 demonstrated a 75% overall response rate in a Phase 1 trial involving patients with advanced metastatic castration-resistant prostate cancer. This promising early result highlights the...





